• Customer Care
  • (888) 123-4567


At Rise Therapeutics, we develop targeted immunological-based biologics using a unique and proprietary oral delivery platform. We design and produce unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity, infection, and cancer.

Rise Therapeutics Hires Sathya Janardhanan, MS as Vice President of Development and Manufacturing

Rockville, MD. Rise Therapeutics, a synthetic biology company developing targeted immunological-based biologics using a unique and proprietary oral delivery platform, today announced the appointment of Sathya Janardhanan, MS, as Vice President of Development and Manufacturing.

“Sathya is an experienced leader in designing drug manufacturing processes, facilities, and product quality characterization, and he has advanced multiple novel biological therapies into Phase I and Phase II clinical trials,” said Gary Fanger, PhD., CEO and President of Rise Therapeutics. “His guidance and expertise will be invaluable as we identify new immune regulatory pathways and develop unique, first-in-class immune modulatory drugs.”

Mr. Janardhanan joins Rise after having founded and managed Apsis Healthcare, a process & analytical technology startup that worked on design, development, and consulting in biopharmaceutical manufacturing technology areas. During his time at Apsis Healthcare, he developed novel analytical instrumentation and contributed to large partnerships that secured NIH grants in the area of online quality attribute detection for biopharmaceutical production processes. Prior to Apsis Healthcare, Sathya was a senior scientist at NextCure, where he worked on all aspects of process, analytical and manufacturing development, while also leading a team that produced the facility’s process automation. Earlier in his career, Sathya Janardhanan held several positions in the areas of protein chemistry, analytical validation, and manufacturing at AstraZeneca and Amplimmune.

“I look forward to working closely with the Rise Therapeutics team to improve the lives of patients. The breadth of scientific expertise combined with an emerging state-of-art flexible manufacturing facility for microbiome-associated Live Biotherapeutic Products positions the company for significant growth,” said Sathya. “It is extremely exciting to be part of the pioneering approach Rise is implementing to develop first-in-class immune modulatory therapeutics.”

Sathya Janardhanan received his Master of Science degree in Chemical and Biomolecular Engineering from University of Maryland College Park and a Bachelor’s degree in Chemical Engineering from National Institute of Technology in India. Sathya is an active reviewer of biomanufacturing guidance documents at the American Society of Testing Methods (ASTM) and leads consortiums related to rapid microbial methods at National Institute of Standards and Technology (NIST) and fulfils professional duties in technical organizations such as Advanced Regenerative Manufacturing Institute (ARMI) / BioFab USA.


About Rise Therapeutics 

Rise Therapeutics is a privately held biotechnology company located in Rockville, Maryland. Rise is pioneering synthetic biology methodologies to develop novel cellular-based medicines. Rise Therapeutics leverages its unique and proprietary TriPartite X (TPX) approach to deliver targeted biologics orally, a novel step forward in the context of protein-based medicines. As a platform drug delivery approach, TPX is ideally suited to deliver any biological therapy orally and, in the context of Rise’s therapeutics product development interests, targeting immunology regulated by the gut microbiome is a key breakthrough that gives Rise a competitive drug development advantage. Rise is currently focused on developing treatments for autoimmunity, inflammatory disease, infection, and cancer. These disease areas represent a large unmet need, both in the United States and around the world. For more information about Rise Therapeutics, please visit www.risetherapeutics.com.